FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000497104> ?p ?o ?g. }

• W3000497104 endingPage "e0227041" @default.
• W3000497104 startingPage "e0227041" @default.
• W3000497104 abstract "We evaluated antiviral therapy (AVT) eligibility in a population-based sample of adults with chronic hepatitis B virus (HBV) infection in Zambia.Using a household survey, adults (18+ years) were tested for hepatitis B surface antigen (HBsAg). Sociodemographic correlates of HBsAg-positivity were identified with multivariable regression. HBsAg-positive individuals were referred to a central hospital for physical examination, elastography, and phlebotomy for HBV DNA, hepatitis B e antigen, serum transaminases, platelet count, and HIV-1/2 antibody. We determined the proportion of HBV monoinfected adults eligible for antiviral therapy (AVT) based on European Association for the Study of the Liver (EASL) 2017 guidelines. We also evaluated the performance of two alternative criteria developed for use in sub-Saharan Africa, the World Health Organization (WHO) and Treat-B guidelines.Across 12 urban and 4 rural communities, 4,961 adults (62.9% female) were tested and 182 (3.7%) were HBsAg-positive, 80% of whom attended hospital follow-up. HBsAg-positivity was higher among men (adjusted odds ratio [AOR], 1.37; 95% confidence interval [CI], 0.99-1.87) and with decreasing income (AOR, 0.89 per household asset; 95% CI, 0.81-0.98). Trends toward higher HBsAg-positivity were also seen at ages 30-39 years (AOR, 2.11; 95% CI, 0.96-4.63) and among pregnant women (AOR, 1.74; 95% CI, 0.93-3.25). Among HBV monoinfected individuals (i.e., HIV-negative) evaluated for AVT, median age was 31 years, 24.6% were HBeAg-positive, and 27.9% had HBV DNA >2,000 IU/ml. AVT-eligibility was 17.0% by EASL, 10.2% by WHO, and 31.1% by Treat-B. Men had increased odds of eligibility. WHO (area under the receiver operating curve [AUROC], 0.68) and Treat-B criteria (AUROC, 0.76) had modest accuracy. Fourteen percent of HBsAg-positive individuals were HIV coinfection, and most coinfected individuals were taking tenofovir-containing antiretroviral therapy (ART).Approximately 1 in 6 HBV monoinfected adults in the general population in Zambia may be AVT-eligible. Men should be a major focus of hepatitis B diagnosis and treatment. Further development and evaluation of HBV treatment criteria for resource-limited settings is needed. In settings with overlapping HIV and HBV epidemics, scale-up of ART has contributed towards hepatitis B elimination." @default.
• W3000497104 created "2020-01-23" @default.
• W3000497104 creator A5003795150 @default.
• W3000497104 creator A5020288318 @default.
• W3000497104 creator A5048189489 @default.
• W3000497104 creator A5048926174 @default.
• W3000497104 creator A5053192715 @default.
• W3000497104 creator A5064991588 @default.
• W3000497104 creator A5066136225 @default.
• W3000497104 creator A5067719314 @default.
• W3000497104 creator A5074614154 @default.
• W3000497104 creator A5090096669 @default.
• W3000497104 date "2020-01-13" @default.
• W3000497104 modified "2023-09-25" @default.
• W3000497104 title "Eligibility for hepatitis B antiviral therapy among adults in the general population in Zambia" @default.
• W3000497104 cites W1799522345 @default.
• W3000497104 cites W1945511967 @default.
• W3000497104 cites W1963574721 @default.
• W3000497104 cites W1997865776 @default.
• W3000497104 cites W2041626675 @default.
• W3000497104 cites W2046794158 @default.
• W3000497104 cites W2087944742 @default.
• W3000497104 cites W2096083611 @default.
• W3000497104 cites W2098658501 @default.
• W3000497104 cites W2171873429 @default.
• W3000497104 cites W2462340700 @default.
• W3000497104 cites W2475385134 @default.
• W3000497104 cites W2519582915 @default.
• W3000497104 cites W2560535261 @default.
• W3000497104 cites W2572400391 @default.
• W3000497104 cites W2605785536 @default.
• W3000497104 cites W2619890394 @default.
• W3000497104 cites W2639723833 @default.
• W3000497104 cites W2735904513 @default.
• W3000497104 cites W2739640246 @default.
• W3000497104 cites W2782913746 @default.
• W3000497104 cites W2790663016 @default.
• W3000497104 cites W2810470127 @default.
• W3000497104 cites W2909795031 @default.
• W3000497104 cites W2922875643 @default.
• W3000497104 cites W2939355228 @default.
• W3000497104 doi "https://doi.org/10.1371/journal.pone.0227041" @default.
• W3000497104 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6957183" @default.
• W3000497104 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31929556" @default.
• W3000497104 hasPublicationYear "2020" @default.
• W3000497104 type Work @default.
• W3000497104 sameAs 3000497104 @default.
• W3000497104 citedByCount "12" @default.
• W3000497104 countsByYear W30004971042020 @default.
• W3000497104 countsByYear W30004971042021 @default.
• W3000497104 countsByYear W30004971042022 @default.
• W3000497104 countsByYear W30004971042023 @default.
• W3000497104 crossrefType "journal-article" @default.
• W3000497104 hasAuthorship W3000497104A5003795150 @default.
• W3000497104 hasAuthorship W3000497104A5020288318 @default.
• W3000497104 hasAuthorship W3000497104A5048189489 @default.
• W3000497104 hasAuthorship W3000497104A5048926174 @default.
• W3000497104 hasAuthorship W3000497104A5053192715 @default.
• W3000497104 hasAuthorship W3000497104A5064991588 @default.
• W3000497104 hasAuthorship W3000497104A5066136225 @default.
• W3000497104 hasAuthorship W3000497104A5067719314 @default.
• W3000497104 hasAuthorship W3000497104A5074614154 @default.
• W3000497104 hasAuthorship W3000497104A5090096669 @default.
• W3000497104 hasBestOaLocation W30004971041 @default.
• W3000497104 hasConcept C126322002 @default.
• W3000497104 hasConcept C156957248 @default.
• W3000497104 hasConcept C203014093 @default.
• W3000497104 hasConcept C2522874641 @default.
• W3000497104 hasConcept C2775940106 @default.
• W3000497104 hasConcept C2777382497 @default.
• W3000497104 hasConcept C2777410769 @default.
• W3000497104 hasConcept C2780593183 @default.
• W3000497104 hasConcept C2908647359 @default.
• W3000497104 hasConcept C44249647 @default.
• W3000497104 hasConcept C71924100 @default.
• W3000497104 hasConcept C99454951 @default.
• W3000497104 hasConceptScore W3000497104C126322002 @default.
• W3000497104 hasConceptScore W3000497104C156957248 @default.
• W3000497104 hasConceptScore W3000497104C203014093 @default.
• W3000497104 hasConceptScore W3000497104C2522874641 @default.
• W3000497104 hasConceptScore W3000497104C2775940106 @default.
• W3000497104 hasConceptScore W3000497104C2777382497 @default.
• W3000497104 hasConceptScore W3000497104C2777410769 @default.
• W3000497104 hasConceptScore W3000497104C2780593183 @default.
• W3000497104 hasConceptScore W3000497104C2908647359 @default.
• W3000497104 hasConceptScore W3000497104C44249647 @default.
• W3000497104 hasConceptScore W3000497104C71924100 @default.
• W3000497104 hasConceptScore W3000497104C99454951 @default.
• W3000497104 hasFunder F4320308573 @default.
• W3000497104 hasFunder F4320337356 @default.
• W3000497104 hasIssue "1" @default.
• W3000497104 hasLocation W30004971041 @default.
• W3000497104 hasLocation W30004971042 @default.
• W3000497104 hasLocation W30004971043 @default.
• W3000497104 hasLocation W30004971044 @default.
• W3000497104 hasOpenAccess W3000497104 @default.
• W3000497104 hasPrimaryLocation W30004971041 @default.
• W3000497104 hasRelatedWork W1948134277 @default.

• next